Since it was first reported in 1994 that KRAS mutations identical to those in tumor tissues were detectable in the plasma cfDNA of a patient with pancreatic cancer, research on ctDNA has advanced rapidly [5]. This evidence concerns the gene KRAS and pancreatic neoplasm.